Small cell lung cancer(SCLC) originates from neuroendocrine cell precursors within the bronchi and is characterized by its highly aggressive nature,a high risk of recurrence,and a high proliferation rate. Over the past 3 decades,systemic treatment options for SCLC have undergone few changes in that therapeutic options are limited and have nearly reached the stage of a bottleneck. Therefore,safe and novel therapies are urgently needed in clinical practice. Recently,clinical research has shown that immunother...